Quick Order
UCHL3 protein-HIS Epitope
Description
Background
UCHL3 or ubiquitin carboxyl-terminal esterase L3 (ubiquitin thiolesterase) is a member of the deubiquitinating enzyme family that catalyze the removal of ubiquitin from polypeptides. The deubiquitinating enzyme family is divided into five classes, depending on the mechanism of catalysis. UCHL3 has been implicated in the etiology of neurodegeneration (1). UCHL3 may hydrolyze the ubiquitinyl-N-epsilon amide bond of ubiquitinated proteins to regenerate ubiquitin for another catalytic cycle and UCHL3 genes contain a conserved CpG island (2). UCHL1 Protein is ideal for investigators involved in Signaling Proteins, Ubiquitin Proteins, Angiogenesis, Apoptosis/Autophagy, Cancer, Cell Cycle, Cellular Stress, Inflammation, Invasion/Metastasis, and Neurobiology research.
Application Note
UCHL3 Protein is stored in 50mM sodium phosphate, pH 7.0, 300mM NaCl, 150mM imidazole, 0.1mM PMSF, 0.25mM DTT, 25% glycerol. UCHL3 Protein is suitable for use in Western Blot. Expect a band approximately ~27kDa on specific lysates or tissues. Specific conditions for reactivity should be optimized by the end user.
Purity/Specificity
Recombinant full-length human UCHL3 was expressed by E. coli cells using an N-terminal his epitope. The purity was determined to be >95% by densitometry.
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.